Bepirovirsen shows 61% functional cure rate in Chinese HBV patients

The 61% functional cure rate in a Chinese cohort is a meaningful data point for the hepatitis B treatment landscape, suggesting potential regional efficacy differences that could influence regulatory and clinical adoption beyond Japan's prior approval. This primarily affects hepatology-focused biopharma stakeholders and the broader antiviral market, where functional cure—rather than viral suppression—has been a long-sought endpoint. The open question is whether this efficacy translates across other Asian and global populations, and how it positions against competing candidates in late-stage development. Watch for upcoming full B-Well results and subsequent regulatory filings as the next catalysts.